We employed a three-stage modelling approach , which included development of ( @ ) a baseline @-h ABPM model , ( @ ) a pharmacokinetic model from serial and sparse pharmacokinetic data , and ( @ ) an indirect-response , maximum-effect ( Emax ) model to evaluate the exposure-driven effect of axitinib on dBP .